These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34893821)
1. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019. Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821 [TBL] [Abstract][Full Text] [Related]
2. Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria. Egger M; Gornicec M; Wölfler A; Lembeck AL; Tinchon C; Maderdonner M; Prattes J Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36029283 [TBL] [Abstract][Full Text] [Related]
3. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration. Walker C; Horowitz A; Nooruddin Z; Frei CR J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168 [TBL] [Abstract][Full Text] [Related]
4. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study. Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556 [TBL] [Abstract][Full Text] [Related]
5. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Holowka T; Cheung H; Malinis M; Gan G; Deng Y; Perreault S; Isufi I; Azar MM J Infect Chemother; 2021 Dec; 27(12):1700-1705. PubMed ID: 34389223 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465 [TBL] [Abstract][Full Text] [Related]
7. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Chamilos G; Lionakis MS; Kontoyiannis DP Clin Infect Dis; 2018 Jan; 66(1):140-148. PubMed ID: 29029010 [TBL] [Abstract][Full Text] [Related]
8. Secondary invasive fungal infection in hospitalised patients with COVID-19 in the United States. Thompson GR; Miceli MH; Jiang J; Shortridge EF; Davies K; Gurumoorthy G; Kimura T Mycoses; 2023 Jun; 66(6):527-539. PubMed ID: 36808656 [TBL] [Abstract][Full Text] [Related]
9. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors. Zarakas MA; Desai JV; Chamilos G; Lionakis MS Curr Fungal Infect Rep; 2019 Sep; 13(3):86-98. PubMed ID: 31555394 [TBL] [Abstract][Full Text] [Related]
11. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis. Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308 [TBL] [Abstract][Full Text] [Related]
12. Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use. Asawa P; Chahine Z; Vusqa U; Samhouri Y; Fazal S J Oncol Pharm Pract; 2022 Oct; 28(7):1654-1658. PubMed ID: 35253502 [No Abstract] [Full Text] [Related]